A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
Condition:   Lassa Fever Interventions:   Drug: Day 1 Lower Dose (2×106 pfu);   Drug: Day 1 Higher Dose (1×107 pfu);   Drug: Placebo Sponsors:   International AIDS Vaccine Initiative;   Coalition for Epidemic Preparedness Innovations Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2023 Category: Research Source Type: clinical trials

INOVIO Provides an Update on Lassa Fever and MERS Programs
PLYMOUTH MEETING, Pa., Nov. 17, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2022 Category: Pharmaceuticals Source Type: clinical trials

Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever
Condition:   Lassa Fever Interventions:   Drug: Ribavirin iv;   Drug: Favipiravir Sponsors:   Bernhard Nocht Institute for Tropical Medicine;   University of Hamburg;   Alliance for International Medical Action;   Institut National de la Santé Et de la Recherche Médicale, France;   University of Bordeaux;   Federal Medical Centre, Owo;   Irrua Specialist Teachin g Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 1, 2021 Category: Research Source Type: clinical trials